Healthequity Inc (NASDAQ:HQY) EVP Delano Ladd sold 26,405 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $43.32, for a total value of $1,143,864.60. Following the completion of the sale, the executive vice president now directly owns 16,692 shares of the company’s stock, valued at $723,097.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Healthequity Inc (HQY) opened at $45.89 on Friday. The company has a market capitalization of $2,718.13, a P/E ratio of 64.00, a price-to-earnings-growth ratio of 1.86 and a beta of 1.74. Healthequity Inc has a one year low of $37.62 and a one year high of $55.31.
Healthequity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, December 5th. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.04. The firm had revenue of $56.80 million during the quarter, compared to the consensus estimate of $55.27 million. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. The firm’s revenue was up 31.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.10 EPS. analysts predict that Healthequity Inc will post 0.71 EPS for the current year.
HQY has been the subject of several research reports. Zacks Investment Research raised Healthequity from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Wednesday, October 11th. BidaskClub raised Healthequity from a “sell” rating to a “hold” rating in a report on Thursday, September 28th. Cantor Fitzgerald reissued a “buy” rating and issued a $56.00 target price on shares of Healthequity in a report on Tuesday, August 29th. Robert W. Baird reissued a “hold” rating on shares of Healthequity in a report on Thursday, September 21st. Finally, Oppenheimer reissued a “buy” rating and issued a $61.00 target price on shares of Healthequity in a report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $58.33.
Healthequity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.